Neuroprotective Effects of Modafinil on MPTP Mouse Model of Parkinson's Disease

Abstract

Abstract: Aim To observe the neuroprotective effects of modafinil on the Parkinson's disease ( PD ) model induced by 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Methods The model of PD was induced by intraperitoneal injection of MPTP into C57BL/6J mice for4 d. Modafinil (ip, 50 or 100 mg·kg^-1·d^-1) was administered following MPTP for 4 d and for another 10 d consecatirely. The effects of modafinil on the locomotor activity, and the incubation, maintenance period and grade of the tremor, the duration of the climbing rod of mouse, and the distribution of positive cells of tyrosine hydroxylase (TH) and Nissl bodies in the striatum and substantia nigra (SN) were observed. The contents of dopamine (DA) , noradrenaline (NA) and 5-hydroxytryptamine (5-HT) in the striatum were determined. Results Modafinil (50 and 100 mg·kg^-1) significantly prevented the locomotor, the tremor and climbing rod defect behavior in a dose-dependent nanner (P<0.05 and P<0.01, n = 10), prevented the decrease in the number of TH-positive cells and Nissl bodies (P<0.05, n = 10), and reduced the decrease of DA, NA, and 5-HT in the striatum (P<0.05, n = 10) induced by MPTP. Conclusion Modafinil improves the behavioral deficits and prevents the monoaminergic neuron lesion in seriously impaired MPTP mouse model.

Key words: MPTP, MPTP, Parkinson's disease, Parkinson's disease, modafinil, modafinil, dopamine, dopamine, tyrosine hydroxylase, tyrosine hydroxylase, Nissl bodies, Nissl bodies

CLC Number:

R965

R971.5

Supporting:

XIAO Yan-li^*, DONG Zhi, FU Jie-min, ZHOU Qi-xin, LIAO Hong. Neuroprotective Effects of Modafinil on MPTP Mouse Model of Parkinson's Disease[J]. .

References

[1] Fahn S, Przedborski S. Merritt’s neurology [A]. In Rowland LP, ed. Parkinosonism[M]. New York: Lippincott Williams and Wilkins, 2000. 679-693.
[2] Robertson PJ, Hellriegel ET. Clinical pharmacokinetic profile of modafinil [J]. Clin Pharmacokinet 2003, 42 (2): 123.
[3] Happe S, Pirker W, Sauter C, et al. Successful treatment of excessive daytime sleepiness in Parkinson’s disease with modafinil [J]. J Neurol, 2001, 248 (7): 632.
[4] Lallenment G, Pierard C, Masqueliez C, et al. Neuroprotective effect of modafinil against soman-induced hippocampal lesions [J]. Med Sci Res, 1997, 25 (4): 437.
[5] Fuxe K, Ueki A, Rosen L, et al. Evidence for a preventive action of the vigilance-promoting drug modafinil against striatal ischemic injury induced by endothelin-1 [J]. Exp Brain Res,1993, 96 (1): 89.
[6] Lagarde D, Trocherie S, Morlet T, et al. Evaluation of the effects of modafinil in hypobaric hypoxia in rhesus monkeys [J]. Med Sci Res, 1993, 21 (6): 633.
[7] Fuxe K, Ueki A, Rosen L, et al. The vigilance-promoting drug modafinil counteracts the reduction of tyrosine hydroxylase immunoreactivity and of dopamine stores in nigrostriatal dopamine neurons in the male rat after a partial transection of the dopamine pathway [J]. Exp Brain Res, 1993, 93 (2): 259.
[8] Aguirre JA, Cintra A, Hillion J, et al. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse [J]. Neurosci Lett, 1999, 275 (3): 215.
[9] Jenner P, Zeng BY, Smith LA, et al. Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset [J]. Exp Brain Res, 2000, 133 (2): 178.
[10] Fuxe K, Janson AM, Rosen L, et al. Evidence for a protective action of the vigilance-promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemial and biochemical analysis [J]. Exp Brain Res, 1992, 88 (1): 117.
[11] Przedborski S, Jackson-Lewis V, Djaldetti R, et al. The parkinsonian toxin MPTP action and mechanism [J]. Restor Neurol Neurosci, 2000, 16 (1): 135.
[12] Bergman H, Deuschl G. Pathophysiology of Parkinson’s disease: from clinical neurology to basic neuroscience and back [J]. Mov Disord, 2002, 17 (Suppl 3): S28.
[13] Sedelis M, Hofele K, Auburger GW, et al. MPTP susceptibility in the mouse: behavioral, neurochemical, and histological analysis of gender and strain differences [J]. Behav Genet, 2000, 30 (3): 171.
[14] Arai N, Misugi K, Goshima Y, et al. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism [J]. Brain Res, 1990, 515(1): 57.
[15] Sundstrom E, Fredriksson A, Archer T. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson’s disease [J]. Brain Res, 1990, 528 (1): 181.
[16] Przedborski S, Jackson-Lewis V, Naini A, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP ): a technical review of its utility and safety [J]. J Neurochem, 2001, 76 (5): 1265.
[17] Grunblatt E, Mandel S, Youdim MB. MPTP and 6-Hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies [J]. J Neurol, 2000, 247(Suppl 2): II95.
[18] Ferraro L, Tanganelli S, Fuxe K, et al. Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs [J]. Brain Res, 2001, 894 (2): 307.
[19] Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil [J]. Neuropharmacology, 2000, 39 (11): 1974.